Copyright
©The Author(s) 2023.
World J Clin Cases. Apr 26, 2023; 11(12): 2740-2752
Published online Apr 26, 2023. doi: 10.12998/wjcc.v11.i12.2740
Published online Apr 26, 2023. doi: 10.12998/wjcc.v11.i12.2740
Figure 1 Hematological variables at baseline and after ferric carboxymaltose treatment.
A: Median of hemoglobin; B: Hematocrit; C: Ferritin; D: Serum iron; E: Transferrin saturation. n = 25. Paired t-test with aP < 0.05; bP < 0.001.
- Citation: Siqueira NSN, Pascoal LB, Rodrigues BL, de Castro MM, Martins ASC, Araújo DOS, Gomes LEM, Camargo MG, Ayrizono MLS, Leal RF. Ferric carboxymaltose for anemia in Crohn’s disease patients at a tertiary center: A retrospective observational cohort study. World J Clin Cases 2023; 11(12): 2740-2752
- URL: https://www.wjgnet.com/2307-8960/full/v11/i12/2740.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i12.2740